<DOC>
	<DOCNO>NCT00978497</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability effectiveness ANA598 administer pegylated interferon ribavirin ( Standard Care [ SOC ] ) compare placebo + SOC .</brief_summary>
	<brief_title>Safety , Tolerability , Antiviral Activity ANA598 Administered Combination With Pegylated Interferon Ribavirin Treatment Genotype-1 Chronic HCV Infection</brief_title>
	<detailed_description>The safety , tolerability antiviral activity ANA598 , administer orally 200 mg BID 400 mg BID 12 week combination pegylated interferon ribavirin ( SOC ) compare placebo + SOC . Treatment-naïve patient genotype 1 infection eligible enrollment . Patients randomized ANA598 receive load dose 800 mg q 12 hour administer first day dose . Patients undetectable HCV RNA week 4 week 12 randomize receive either additional 12 36 week SOC alone . Ninety patient randomize 2 cohort . The forty-five patient cohort randomize 30 active : 15 placebo .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Male female , age 18 65 year Documented chronic HCV infection , genotype 1a 1b Treatmentnaïve Female patient pregnant breastfeed Infection nongenotype 1 HCV Previous treatment HCV infection HIV HBV positive Any medical contraindication PegIFN RBV therapy History know cause liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>